NCT02310399 · NYU Langone Health
Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves
What this study is about
This study is a feasibility study of the Nucleus 24 ABI in children without NF2. It will be conducted as a repeated-measures, single subject experiment in order to accommodate the known variability in cochlear implant clinical results.
View original scientific description
This study is a feasibility study of the Nucleus 24 ABI in children without NF2. It will be conducted as a repeated-measures, single subject experiment in order to accommodate the known variability in cochlear implant clinical results. Data obtained in the course of this study will be compared with the existing published outcome data from children with normal hearing and with cochlear implants (CIs). These comparisons may provide additional useful information about the progress of ABI subjects' performance over time. Also, this may allow the results of the current study to be utilized to design future pivotal studies of the device in the pediatric population.
Interventions
DEVICE
Nucleus ABI541 Auditory Brainstem Implant
Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
Primary outcome measures
ABI Device Complications
Time frame: 5 Years from date of surgery
Study participants will be monitored on a case-by-case basis for ongoing or unanticipated medical complications. Adverse events will be tracked on a case-by-case basis and recorded at the time of occurrence and followed up at resolution. Any adverse events will be reported to the NYUSOM IRB. Should there be concern for the safety of the subjects because of their participation in the study by the investigators or the IRB, the study would be halted at least temporarily and a detailed discussion with the investigators and the IRB would be undertaken.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Group 1: Prelinguistic hearing loss (birth-5 years; age at implantation of ABI 18 months-5 years) • Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both:
- MRI +/- CT evidence of one of the following:
- Cochlear nerve deficiency
- Cochlear aplasia or severe hypoplasia
- Severe inner ear malformation
- Post-meningitis ossification
- When a cochlea is present or patent, lack of significant benefit from CI despite consistent use (\>6 mo.)
- No or limited speech perception ability (limited to pattern perception on closed set testing materials using the CI)
- Lack of progress in auditory skills development Group 2: Post-linguistic hearing loss (\<21 yrs. of age)
- Post-linguistic hearing loss (\<21 yrs. of age) with:
- Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation. Examples might include:
- Post-meningitis ossification
- Bilateral temporal bone fractures with cochlear nerve avulsion
- Failed revision CI without benefit
- Previously developed open set speech perception and auditory-oral language skills
- No medical contraindications
- Willing to receive the appropriate meningitis vaccinations
- No or limited cognitive/developmental delays.
- Strong family support
- Reasonable expectations from parents/guardians including a thorough understanding:
- of potential benefits and limitations of ABI
- of parental role in rehabilitation
- that the child may not develop spoken language as a primary communication mode or even sufficient spoken language to make significant academic progress in an aural/oral environment
- Involvement in a rehabilitation program that emphasizes development of auditory skills with or without the use of supplementary visual communication.
- Able to comply with study requirements including travel to investigation sites.
- Informed consent for the procedure from the child's parents/legal guardian.
Exclusion criteria
- For both Groups 1 and 2:
- Pre- or post-linguistic child currently making significant progress with CI Even for the very young children (18 months of age with 6 months of use), nearly all children with a good auditory signal from their CI will show evidence of improvement in these metrics over time.
- MRI evidence of one of the following:
- normal cochlea and cochlear nerves or NF2
- brainstem or cortical anomaly that makes implantation unfeasible
- Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI.
- Intractable seizures or progressive, deteriorating neurological disorder
- Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a
- Patients with any foreseeable need for a future MRI scan
- Unable to participate in behavioral testing and mapping with their CI. If this appears to be an age effect, ABI will be delayed until we can be assured that the child will be able to participate, as reliable objective measures of mapping are currently not available for mapping these devices.
- Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.).
- Need for brainstem irradiation
- Unrealistic expectations on the part of the subject/family regarding the possible benefits, risks and limitations inherent to the procedure and ABI device.
- Unwilling to sign the informed consent.
- Unwilling to make necessary follow-up appointments.
Where
- New York, New York
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Oct 30, 2025 · Source of record for eligibility and locations